BC Innovations | Nov 16, 2017
Translation in Brief

Lighting up the DYRK

Kyoto University researchers have described a DYRK1A inhibitor that could treat neuronal deficits in Down syndrome with fewer side effects than other inhibitors of the kinase -- but neurology company NeuroNascent Inc. suggests the safety...
BC Innovations | Feb 5, 2015
Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
BC Innovations | Sep 26, 2013
Targets & Mechanisms

Hedgehog battles Down syndrome

Researchers at The Johns Hopkins University School of Medicine have proposed that mental retardation caused by Down syndrome could be prevented or mitigated after birth with a small molecule activator of the sonic hedgehog homolog...
BC Innovations | Mar 7, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Cognitive dysfunction GABAA receptor a5 (GABRA5) Mouse studies suggest selective GABRA5 negative allosteric modulators could help treat cognitive dysfunction in Down...
BC Week In Review | Mar 4, 2013
Clinical News

Roche preclinical data

In a mouse model of Down syndrome, RO4938581 reversed neurological deficits in spatial learning and memory and improved abnormalities of nerve cell number and function vs. vehicle-treated controls. RO4938581 also suppressed hyperactivity without inducing anxiety...
BC Week In Review | Oct 22, 2012
Clinical News

RG1662: Phase I started

In its 3Q12 earnings, Roche said that it began a Phase I trial evaluating RG1662 in 17 patients and healthy volunteers. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: RG1662   Business: Neurology   Molecular target:...
BC Week In Review | Oct 22, 2012
Clinical News

RG1662: Phase I started

In its 3Q12 earnings, Roche said that it began a Phase I trial to evaluate multiple doses of RG1662 over 28 days in 6 healthy volunteers. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: RG1662  ...
BioCentury | Oct 8, 2012
Product Development

Contrarian thinking

While many pharma companies are exiting or externalizing neurology R&D, a few have decided to double down, seeing the glimmer of a new understanding of CNS diseases where others see biological black boxes leading to...
BC Week In Review | Sep 19, 2011
Clinical News

RG1662: Phase I started

Roche began a double-blind, placebo-controlled Phase I trial to evaluate multiple doses of oral RG1662 for 38 days in about 33 Down syndrome patients ages 18-30. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: RG1662  ...
BC Innovations | Oct 21, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) GABAA receptor; apolipoprotein E (APOE) A study in mice suggests that increasing signaling through the GABAA receptor could help treat APOE variant...
Items per page:
1 - 10 of 10